# Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations

> **NCT06969963** · PHASE1 · COMPLETED · sponsor: **Aya Mohammed Abdel Magid Abdel Hamid** · enrollment: 26 (actual)

## Conditions studied

- Bioequivalence Study in Healthy Subjects

## Interventions

- **DRUG:** Lepsiramp, 0.5 Mg/mL Oral Suspension
- **DRUG:** Fycompa, 0.5 Mg/mL Oral Suspension

## Key facts

- **NCT ID:** NCT06969963
- **Lead sponsor:** Aya Mohammed Abdel Magid Abdel Hamid
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-07
- **Primary completion:** 2024-07-23
- **Final completion:** 2024-07-23
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-08-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06969963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06969963, "Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06969963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*